At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 45 enrolled
Drug / intervention
Eszopiclone +1 moredrug
Likely dose
Eszopiclone 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Eszopiclone (Lunesta) on Sleep Disturbance and Pain in Cancer
In Brief
A Phase 4 clinical trial evaluating Eszopiclone and Placebo for Sleep Initiation and Maintenance Disorders. Completed, enrolled 45 participants across 1 site.
Detailed Summary
To assess the effectiveness of Lunesta on cancer patients who have received chemotherapy and who require patient controlled analgesia (PCA), specifically to assess whether Lunesta will: * improve sleep thereby decreasing need for opiates via PCA * improve sleep thereby decreasing pain by self report * improve sleep thereby decreasing fatigue by self report
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2006
Enrollment StartSep 2006
Primary CompletionDec 2009
TodayJul 2026
First PostedAug 17, 2006
Enrollment StartSep 1, 2006
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 19.9 years ago
Interventions
Eszopiclonedrug
eszopiclone 2 to 3 mg po at bedtime
Placebodrug
placebo 2 to 3 mg po at bedtime